Fondaparinux Sodium

Indications

Deep Vein Thrombosis

Fondaparinux Sodium is a Factor Xa inhibitor, which is a type of anticoagulant. It is used for prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery or abdominal surgery. It is also indicated for treatment of prophylaxis of deep vein thrombosis (DVT) or acute pulmonary embolism (PE) when it is given in conjunction with warfarin.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Fondaparinux Sodium works against clots by selectively inhibiting Factor Xa. It binds selectively to antithrombin III (ATIII), and this raises (by about 300 times) the natural neutralization of Factor Xa that ATIII already carries out. Once Factor Xa is neutralized, the blood coagulation cascade is interrupted, so thrombin formation and thrombus development are held back.

Fondaparinux Sodium does not inactivate thrombin (activated Factor II), and it has no known effect on platelet function. At the recommended dose, it doesn't affect fibrinolytic activity or bleeding time.

Pregnancy & Breastfeeding

Fondaparinux sodium is Pregnancy Category B. Nobody knows yet whether it passes into human breast milk, so a nursing mother should be given Fondaparinux Sodium with caution.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Prophylaxis of deep vein thrombosis: the dose of Fondaparinux is 2.5 mg subcutaneously once daily, given after hemostasis has been established. The first dose should be given no earlier than 6 to 8 hours after surgery, and treatment continues for 5 to 9 days. For patients undergoing hip fracture surgery, extended prophylaxis of up to 24 additional days is recommended. Treatment of deep vein thrombosis and pulmonary embolism: Fondaparinux is given subcutaneously once daily, and the dose depends on body weight. It is 5 mg for patients under 50 kg (<50 kg), 7.5 mg for 50 to 100 kg, and 10 mg for over 100 kg (>100 kg). Treatment should continue for at least 5 days, until an INR of 2 to 3 is achieved with warfarin sodium. Pediatric use: the safety and effectiveness of Fondaparinux Sodium in pediatric patients have not been established. Geriatric use: in clinical trials, Fondaparinux Sodium worked about as well in the elderly (65 years or older) as in patients younger than 65 years, however, serious adverse events increased with age. Use in renal or hepatic impairment: the risk of bleeding is higher when renal or hepatic function is reduced.